| abstract |
[PROBLEMS] An improved agent for the prevention and treatment of diseases associated with deposition of β-amyloid peptide (Aβ) in cerebral nerve cells, that is, Alzheimer's disease related to amyloidogenic disorder, and neuritic dystrophy. And providing a method. A variable framework region from a human acceptor immunoglobulin light chain comprising two immunoglobulin light chain variable regions and a heavy chain variable region complementarity determining region that specifically binds to an Aβ peptide. A humanized immunoglobulin comprising, or an antigen-binding fragment thereof. And a pharmaceutical composition comprising the peptide. [Selection figure] None |